Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 8Sarcoma 3Gastrointestinal 2Thoracic 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 9481Triple Negative Breast Neoplasms 635Neoplasms 413Lung Neoplasms 342Prostatic Neoplasms 321Ovarian Neoplasms 299Colorectal Neoplasms 289Neoplasm Metastasis 280Motor Activity 267Carcinoma, Intraductal, Noninfiltrating 231Colonic Neoplasms 193Breast Neoplasms, Male 172Lymphedema 170Melanoma 158Pancreatic Neoplasms 152Breast Carcinoma In Situ 151Carcinoma, Non-Small-Cell Lung 149Uterine Cervical Neoplasms 144Fatigue 140Head and Neck Neoplasms 132Pain 122Breast Cancer Female 122Brain Neoplasms 118Stomach Neoplasms 117Sarcoma 106Depression 105Breast Cancer Lymphedema 101Anxiety Disorders 101Lymphoma 96Cardiotoxicity 89

Interventions

palbociclib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Endometrioid × Breast × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡